Skip to main content
NVDA+0.35%AAPL-0.21%GOOGL+0.59%MSFT-0.53%AMZN+0.04%TSM-1.68%SPCX+0.43%AVGO-0.97%META-0.25%TSLA+0.05%SKHY-5.20%MU+0.17%BRK-B+0.06%LLY-0.10%JPM-0.32%WMT-0.09%AMD-3.36%V-0.05%XOM+0.61%ASMLa-1.66%JNJ-0.27%INTC-5.57%MA-0.38%0700.HK-1.94%1398.HK+0.79%ABBV+1.62%BAC-0.18%ORCL-5.23%CVX-0.50%CSCO-1.82%COST-0.02%KO+0.32%LRCX-5.65%CAT-1.29%AP2d-1.55%0005.HK-0.78%AMAT-3.17%HSBA.L-1.30%UNH-1.22%PG+0.25%DELL-5.35%GE-0.39%MS-1.22%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.03%HD-1.53%0939.HK+1.66%GS-0.88%NZDJPY-2.56%AUDJPY-1.80%CHFJPY-1.58%NZDCAD-1.40%NZDUSD-1.35%EURNZD+1.34%GBPNZD+1.27%GBPJPY-1.26%EURJPY-1.22%USDJPY-1.19%CADJPY-1.15%NZDCHF-0.95%AUDNZD+0.78%AUDCAD-0.68%AUDUSD-0.61%USDTHB+0.60%EURAUD+0.59%GBPAUD+0.54%CADCHF+0.42%GBPTRY+0.41%USDCHF+0.40%EURCHF+0.36%GBPHKD+0.32%GBPCHF+0.32%USDTRY+0.30%GBPMXN-0.28%AUDCHF-0.24%USDILS+0.16%GBPCAD-0.12%USDCNH+0.09%EURCAD-0.07%GBPUSD-0.06%USDCAD-0.04%EURUSD-0.04%USDCOP-0.04%EURGBP+0.04%USDHKD+0.01%USDNOK0.00%EURSEK0.00%GBPSGD0.00%GBPZAR0.00%CHFNOK0.00%EURPLN0.00%PLNJPY0.00%NZDMXN0.00%EURNOK0.00%NZDSGD0.00%EURCZK0.00%SGDJPY0.00%NOKJPY0.00%AUDSGD0.00%USDMXN0.00%EURDKK0.00%USDSEK0.00%USDZAR0.00%EURHKD0.00%AUDNOK0.00%EURCNH0.00%EURZAR0.00%EURSGD0.00%USDDKK0.00%USDPLN0.00%AUDDKK0.00%CHFSGD0.00%CHFSEK0.00%USDSGD0.00%GAGUSD0.00%HG10.00%S10.00%USOIL0.00%W10.00%XAGUSD0.00%XAUUSD0.00%C10.00%XNGUSD0.00%COCOA0.00%COFFEE0.00%COTTON0.00%BTCUSD-1.40%ETHUSD-0.30%USDTUSD-0.02%XRPUSD-2.98%SOLUSD-1.59%TRXUSDT+0.24%ZECUSDT-8.97%DOGEUSD-2.43%XMRUSDT-0.50%LINKUSD-2.06%XLMUSD-2.24%BCHUSDT-10.23%LTCUSD-1.60%UNIUSD-1.82%TONUSD+24.88%HBARUSDT-1.75%SUIUSD-4.16%TAOUSDT-5.64%AAVEUSD-2.53%DOTUSDT-0.67%ICPUSDT+0.58%ONDOUSDT-3.40%WLDUSDT-3.39%ATOMUSDT-2.89%ARBUSDT-1.63%JUPUSDT-2.53%INJUSDT-2.46%STXUSDT-4.89%FETUSDT-2.36%TIAUSDT-2.18%PYTHUSDT-0.25%SEIUSDT-6.02%IMXUSDT-3.85%WIFUSDT-5.38%GRTUSDT-3.50%OPUSDT-4.00%POLUSDT-4.92%IOTAUSDT-4.23%AXSUSDT-2.36%FARTCOINUSDT-3.29%EOSUSDT-2.29%DYDXUSDT-1.42%ORDIUSDT-1.07%GALAUSDT-3.65%NOTUSDT-2.97%RONINUSDT-2.64%NVDA+0.35%AAPL-0.21%GOOGL+0.59%MSFT-0.53%AMZN+0.04%TSM-1.68%SPCX+0.43%AVGO-0.97%META-0.25%TSLA+0.05%SKHY-5.20%MU+0.17%BRK-B+0.06%LLY-0.10%JPM-0.32%WMT-0.09%AMD-3.36%V-0.05%XOM+0.61%ASMLa-1.66%JNJ-0.27%INTC-5.57%MA-0.38%0700.HK-1.94%1398.HK+0.79%ABBV+1.62%BAC-0.18%ORCL-5.23%CVX-0.50%CSCO-1.82%COST-0.02%KO+0.32%LRCX-5.65%CAT-1.29%AP2d-1.55%0005.HK-0.78%AMAT-3.17%HSBA.L-1.30%UNH-1.22%PG+0.25%DELL-5.35%GE-0.39%MS-1.22%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.03%HD-1.53%0939.HK+1.66%GS-0.88%NZDJPY-2.56%AUDJPY-1.80%CHFJPY-1.58%NZDCAD-1.40%NZDUSD-1.35%EURNZD+1.34%GBPNZD+1.27%GBPJPY-1.26%EURJPY-1.22%USDJPY-1.19%CADJPY-1.15%NZDCHF-0.95%AUDNZD+0.78%AUDCAD-0.68%AUDUSD-0.61%USDTHB+0.60%EURAUD+0.59%GBPAUD+0.54%CADCHF+0.42%GBPTRY+0.41%USDCHF+0.40%EURCHF+0.36%GBPHKD+0.32%GBPCHF+0.32%USDTRY+0.30%GBPMXN-0.28%AUDCHF-0.24%USDILS+0.16%GBPCAD-0.12%USDCNH+0.09%EURCAD-0.07%GBPUSD-0.06%USDCAD-0.04%EURUSD-0.04%USDCOP-0.04%EURGBP+0.04%USDHKD+0.01%USDNOK0.00%EURSEK0.00%GBPSGD0.00%GBPZAR0.00%CHFNOK0.00%EURPLN0.00%PLNJPY0.00%NZDMXN0.00%EURNOK0.00%NZDSGD0.00%EURCZK0.00%SGDJPY0.00%NOKJPY0.00%AUDSGD0.00%USDMXN0.00%EURDKK0.00%USDSEK0.00%USDZAR0.00%EURHKD0.00%AUDNOK0.00%EURCNH0.00%EURZAR0.00%EURSGD0.00%USDDKK0.00%USDPLN0.00%AUDDKK0.00%CHFSGD0.00%CHFSEK0.00%USDSGD0.00%GAGUSD0.00%HG10.00%S10.00%USOIL0.00%W10.00%XAGUSD0.00%XAUUSD0.00%C10.00%XNGUSD0.00%COCOA0.00%COFFEE0.00%COTTON0.00%BTCUSD-1.40%ETHUSD-0.30%USDTUSD-0.02%XRPUSD-2.98%SOLUSD-1.59%TRXUSDT+0.24%ZECUSDT-8.97%DOGEUSD-2.43%XMRUSDT-0.50%LINKUSD-2.06%XLMUSD-2.24%BCHUSDT-10.23%LTCUSD-1.60%UNIUSD-1.82%TONUSD+24.88%HBARUSDT-1.75%SUIUSD-4.16%TAOUSDT-5.64%AAVEUSD-2.53%DOTUSDT-0.67%ICPUSDT+0.58%ONDOUSDT-3.40%WLDUSDT-3.39%ATOMUSDT-2.89%ARBUSDT-1.63%JUPUSDT-2.53%INJUSDT-2.46%STXUSDT-4.89%FETUSDT-2.36%TIAUSDT-2.18%PYTHUSDT-0.25%SEIUSDT-6.02%IMXUSDT-3.85%WIFUSDT-5.38%GRTUSDT-3.50%OPUSDT-4.00%POLUSDT-4.92%IOTAUSDT-4.23%AXSUSDT-2.36%FARTCOINUSDT-3.29%EOSUSDT-2.29%DYDXUSDT-1.42%ORDIUSDT-1.07%GALAUSDT-3.65%NOTUSDT-2.97%RONINUSDT-2.64%
EP

Enanta Pharmaceuticals, Inc. (ENTA)

NASDAQ • Healthcare

$12.7
-$0.54 (-4.1%)
Market closed

Last close at September 10, 2026 at 20:00 UTC

Open$13.13
Day Range$12.44 - $13.21
Avg. Volume (3M)235.9K
Market Cap$369.2M
52 Week Range
$7.05$17.15
Next EarningsIn 67 daysNov 16, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$14.3M100%
Gross Profitminus cost of goods$14.3M100%

Fundamentals & Financials

Revenue (TTM)
$65.2M
Net Income (TTM)
-$63.2M
EPS (TTM)
-$2.41
ROA (TTM)
-21.3%
Current Ratio
3.76

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+22.2%Q1 2026-$0.42
+2.2%Q2 2026-$0.45
-31.5%Q3 2026-$0.67
Next

Nov 16

in 67 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

View full earnings history

About Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals, Inc. is a NASDAQ-listed biotechnology company focused on antiviral drug discovery and development. In FY2025, it generated $65.3 million in revenue from a business built around licensed hepatitis C compounds and a pipeline aimed at other viral diseases.

Name
Enanta Pharmaceuticals, Inc.
CEO
Jay R. Luly
Website
www.enanta.com
Industry
Healthcare
Year Founded
1995
Employees
120

Today's Snapshot

AI-generated

The day ended with ENTA 4.1% lower at 12.70, in line with a weaker sector. Trading was busier than usual, with volume about a quarter more than its usual level.

Trading Volume

Above 10d avg 232.9K

312.7K

vs S&P 500 Today

Strong Underperformance

-3.51%

Updated: September 10, 2026 at 20:27 UTC

Technical Indicators

1 Buy2 Neutral5 Sell
ENTA registers a neutral technical profile as the price near 12.70 sits below most moving averages clustered around the mid-teens, indicating recent weakness while ADX remains low and offers little trend conviction. Momentum is mixed: RSI below 40 and CCI deeply negative suggest downside pressure, yet stochastic and Williams %R read as oversold, hinting at potential short-term mean reversion. ATR is moderate and on-balance volume is negative, and the pivot level is above the market, underscoring nearby resistance. Technical takeaway: Neutral — trend and momentum are conflicted, with oversold signals balanced by pervasive moving-average resistance.
All signals
  • EMA (5 indicators)$13.10 - $13.52
    Sell
  • RSI (14)39.55
    Neutral
  • Stochastic %K (14, 3, 3)19.54
    Buy
  • MACD Level (12, 26)0.00
    Neutral

Peers & Related Assets

AVIRAtea Pharmaceuticals, Inc.
$5.18-1.7%
VYGRVoyager Therapeutics, Inc.
$3.19-1.9%
ASMBAssembly Biosciences, Inc.
PRLDPrelude Therapeutics Incorporated
FHTXFoghorn Therapeutics Inc.
PYXSPyxis Oncology, Inc.
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.